Medeon Biodesign (6499) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Medeon Biodesign TWD 10.50, price TWD 79.80, upside -86.8%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medeon Biodesign for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 32.66 TWD – 145.00 TWD · fair‑value band 6.93 TWD – 13.13 TWD · the 79.80 TWD price screens above the 10.50 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Medeon Biodesign in your weekly email
Every Wednesday you see whether Medeon Biodesign is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States.
Show more
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.
Stock analysis
Medeon Biodesign (6499) currently trades at 79.80 TWD, while our model-based Fair Value estimate is 10.50 TWD, 86.8% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 90/100, which puts the evidence level at low.
Scenario range: 6.93 TWD (bear) to 13.13 TWD (bull), the price of 79.80 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Medeon Biodesign reported revenue of 419M TWD in FY2025 versus 69.0M TWD in FY2021, a compound +57.0%/yr. Reported net income was −668M TWD in FY2025.
Key figures
Market cap 7.7B TWD (≈ $243M) · P/S ratio 16.2 · EPS (TTM) −5.92 TWD · Net margin −130% · Return on equity −51.2% · Return on assets (EBIT) −28.2% · Operating margin −132% · Revenue (TTM) 428M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 43% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −87%, 6499 screens richer than that median.
Fair Value models
Bear 6.93 TWDFair Value 10.50 TWDBull 13.13 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+43.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.5%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
’17
’18
’19
’20
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.8% (2020) → −172.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 191 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside−86.8% · Bottom 25%
Profitability
Return on assets−26.1% · Bottom 25%
Net margin (TTM)−130.5% · Bottom 25%
Operating margin (TTM)−131.6% · Bottom 25%
Growth and dividend
Revenue growth−3.4% · Bottom 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B0.16× · Cheapest 25%
P/S (TTM)0.57× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)0· sector 36
PAST (return on equity)0· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medeon Biodesign Fair Value". https://www.fairvalue-calculator.com/stock/6499
Frequently asked questions
Is Medeon Biodesign (6499) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 10.50 TWD versus a price of 79.80 TWD, about −87% upside (overvalued).
What is the fair value of 6499?
Our model-based fair value for Medeon Biodesign is 10.50 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 79.80 TWD.
What is the quality score of 6499?
Medeon Biodesign has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medeon Biodesign (6499)?
Our model-based price target is the fair value of 10.50 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 6.93 TWD, optimistic scenario 13.13 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Medeon Biodesign stock forecast for 2026?
Our models put fair value at 10.50 TWD, about −87% upside versus a price of 79.80 TWD (overvalued). Cautious scenario 6.93 TWD, optimistic scenario 13.13 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Medeon Biodesign (6499)?
Medeon Biodesign reported trailing-twelve-month revenue of about 428M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Medeon Biodesign (6499)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medeon Biodesign it is 10.50 TWD per share (as of Sep 24, 2026), against a price of 79.80 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Medeon Biodesign stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6499 trades above its calculated fair value: price 79.80 TWD, fair value 10.50 TWD, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6499?
No. The price is what the market pays today (79.80 TWD); the fair value is what the company's own numbers justify (10.50 TWD). For Medeon Biodesign the two are 69.30 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Medeon Biodesign worth?
The market values Medeon Biodesign at about 7.7B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 79.80 TWD; our models calculate a fair value of 10.50 TWD per share.
What do the bullish and bearish scenarios say about 6499?
Our models span a range for Medeon Biodesign: cautious scenario 6.93 TWD, base 10.50 TWD, optimistic 13.13 TWD per share (as of Sep 24, 2026, price 79.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medeon Biodesign (6499)?
Balance-sheet figures for Medeon Biodesign (as of Sep 24, 2026): return on equity −51.2%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 6499 from its 52-week high?
Medeon Biodesign trades at 79.80 TWD, about 38% below its 52-week high of 129.00 TWD and 43% above the low of 55.80 TWD (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 10.50 TWD is for.
Which stocks are comparable to Medeon Biodesign?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medeon Biodesign stock attractive at the current price?
The data as of Sep 24, 2026: price 79.80 TWD, calculated fair value 10.50 TWD (−87%), Quality Score 49/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6499 calculated?
We run Medeon Biodesign through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10.50 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Medeon Biodesign itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medeon Biodesign (6499)?
The closing price on Oct 2, 2026 was 79.80 TWD. Our model-based fair value is 10.50 TWD, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medeon Biodesign right now?
The price sits above even our optimistic bull case (13.13 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (6.93 TWD to 13.13 TWD) leaves room in how you read the outcome.
Key figures of Medeon Biodesign
How large is the market capitalisation of Medeon Biodesign (6499)?
The market capitalisation of Medeon Biodesign is 7.7B TWD (≈ $243M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medeon Biodesign (6499)?
The price-to-sales ratio of Medeon Biodesign is 16.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medeon Biodesign (6499)?
Earnings per share at Medeon Biodesign are −5.92 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medeon Biodesign (6499)?
The net margin of Medeon Biodesign is −130% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medeon Biodesign (6499)?
The return on equity (ROE) of Medeon Biodesign is −51.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medeon Biodesign (6499)?
On an EBIT basis the return on assets of Medeon Biodesign is −28.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medeon Biodesign (6499)?
The operating margin of Medeon Biodesign is −132% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medeon Biodesign (6499)?
Revenue at Medeon Biodesign is growing −3.4% versus a year earlier (3y avg +12.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Medeon Biodesign (6499) generate?
The free cash flow of Medeon Biodesign is −646M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Medeon Biodesign in the live analysis
One click puts Medeon Biodesign on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
